Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 55

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 55
---
 of $3.20 per Unit, assuming no exercise of the IPO Warrants issued in connection with this
offering), after deducting the estimated offering expenses payable by us. We cannot predict when or if any of the Units will be sold.

We are offering the 1,562,500 Units on a best-efforts
basis such that the funds received from an investment in this Offering will be available to us immediately for use. Funds will not be
placed in an escrow account and there is no minimum investment that needs to be reached before the funds are available for our use.

We currently anticipate allocating up to 80%
of the net proceeds to research and development activities, including manufacturing, regulatory submissions, and clinical development
for our lead product candidates. The remaining funds will be used for general corporate purposes, including personnel, professional services,
and administrative costs.

Estimated use of proceeds, assuming $600,000 offering expenses
irrespective of the amount sold.

| If 390,625 Units, or 25%, are         
 sold                                  |     |   $1,100,000 |     | Focus on                                                                                                                                 
 critical operations and working capital. We would fund only essential preclinical maintenance activities for Nano-Mupirocin and Nano-ARB 
 programs.                                                                                                                                |
| If 781,250 Units, or 50%, are sold    |     | $  2,200,000 |     | Advance limited development                                                                                                              
 for Nano-Mupirocin (e.g., finalizing CMC plan and IND-enabling studies) and partial funding of Nano-ARB toxicology studies.              |
| If 1,171,875 Units, or 75%, are sold  |     | $  3,300,000 |     | Execute full IND-enabling                                                                                                                
 package for Nano-Mupirocin, initiate tech transfer to CDMO, and fund expanded preclinical studies for Nano-ARB.                          |
| If 1,562,500 Units, or 100%, are sold |     | $  4,400,000 |     | Complete GMP manufacturing                                                                                                               
 and submit IND for Nano-Mupirocin. Initiate Phase 1 trial preparations. Fully fund preclinical activities for Nano-ARB and working       
 capital.                                                                                                                                 |

Set forth below are the estimated amounts
we intend to allocate to each of our product candidates efforts, assuming the full amount of the Primary offering is raised

| Program         |     | Expected                 
 Allocation               |     | Planned